ResMed Inc. (NYSE:RMD) insider James Hollingshead sold 7,019 shares of the company’s stock in a transaction that occurred on Monday, November 20th. The shares were sold at an average price of $84.16, for a total value of $590,719.04. Following the sale, the insider now directly owns 66,409 shares of the company’s stock, valued at $5,588,981.44. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Shares of ResMed Inc. (NYSE:RMD) opened at $85.77 on Friday. ResMed Inc. has a fifty-two week low of $60.13 and a fifty-two week high of $87.81. The company has a current ratio of 4.72, a quick ratio of 3.86 and a debt-to-equity ratio of 0.50. The stock has a market capitalization of $11,969.59, a price-to-earnings ratio of 29.39, a PEG ratio of 1.87 and a beta of 0.78.
ResMed (NYSE:RMD) last released its quarterly earnings data on Thursday, October 26th. The medical equipment provider reported $0.66 EPS for the quarter, meeting the consensus estimate of $0.66. ResMed had a return on equity of 21.53% and a net margin of 16.58%. The company had revenue of $523.66 million for the quarter, compared to analyst estimates of $506.08 million. During the same period last year, the company posted $0.62 earnings per share. The firm’s revenue was up 12.5% compared to the same quarter last year. research analysts expect that ResMed Inc. will post 3 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 14th. Stockholders of record on Thursday, November 9th will be paid a dividend of $0.35 per share. The ex-dividend date is Wednesday, November 8th. This represents a $1.40 annualized dividend and a dividend yield of 1.63%. ResMed’s dividend payout ratio is presently 56.68%.
A number of equities analysts have recently issued reports on the company. Northland Securities restated a “sell” rating and issued a $55.00 price target on shares of ResMed in a report on Friday, October 27th. Jefferies Group restated a “sell” rating and issued a $56.00 price target on shares of ResMed in a report on Thursday, October 12th. Zacks Investment Research upgraded ResMed from a “sell” rating to a “hold” rating in a report on Monday, October 30th. Barclays upped their price target on ResMed from $65.00 to $68.00 and gave the stock an “underweight” rating in a report on Monday, September 25th. Finally, J P Morgan Chase & Co increased their target price on ResMed from $72.00 to $73.00 and gave the company an “overweight” rating in a report on Monday, October 30th. Four analysts have rated the stock with a sell rating, five have issued a hold rating and four have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $67.57.
Several institutional investors have recently made changes to their positions in RMD. Cubist Systematic Strategies LLC acquired a new position in ResMed in the third quarter worth about $113,000. YorkBridge Wealth Partners LLC grew its stake in ResMed by 4.9% in the second quarter. YorkBridge Wealth Partners LLC now owns 1,476 shares of the medical equipment provider’s stock worth $115,000 after purchasing an additional 69 shares in the last quarter. Creative Planning grew its stake in ResMed by 97.1% in the second quarter. Creative Planning now owns 1,671 shares of the medical equipment provider’s stock worth $130,000 after purchasing an additional 823 shares in the last quarter. Toronto Dominion Bank grew its stake in ResMed by 12.8% in the second quarter. Toronto Dominion Bank now owns 1,740 shares of the medical equipment provider’s stock worth $135,000 after purchasing an additional 197 shares in the last quarter. Finally, Huntington National Bank acquired a new position in ResMed in the second quarter worth about $156,000. Institutional investors own 62.02% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “James Hollingshead Sells 7,019 Shares of ResMed Inc. (NYSE:RMD) Stock” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2017/12/08/james-hollingshead-sells-7019-shares-of-resmed-inc-rmd-stock.html.
ResMed Company Profile
ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.
Receive News & Ratings for ResMed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.